Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 1/2020

01-02-2020 | Idiopathic Pulmonary Fibrosis | INTERSTITIAL LUNG DISEASE

The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version

Authors: Karishma S. Hosein, Gianluigi Sergiacomi, Maurizio Zompatori, Marco Mura

Published in: Lung | Issue 1/2020

Login to get access

Abstract

CALIPER is a computer-based quantitative algorithm to accurately characterize and quantify pulmonary fibrosis, and a revised version of composite physiologic index (CPI) has been developed against this new algorithm. The prognostic capabilities of the original and CALIPER-revised versions of CPI were compared in a cohort of 185 patients with IPF prospectively followed in 2 centers. CALIPER-revised CPI was a significant risk factor towards lung transplant (LTx)-free survival, with enhanced hazard ratio (5.68) compared to the original CPI (5.36). Accuracy of LTx-free survival was substantially improved with CALIPER-revised CPI (area under the curve [AUC] 0.75 vs. 0.66), with much better specificity (83% vs. 55%). Six-month changes of CALIPER-revised CPI predicted survival significantly (AUC 0.65). CALIPER-revised CPI is a better predictor of LTx-free survival in patients with IPF. Since CALIPER technology is not available to all centers, this simple and easy to obtain tool may be used to guide management decisions in IPF.
Literature
1.
Fisher J, AlHejaili F, Kendel S, Hirji A, Shapera S, Mura M (2017) Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respir Med 125:65–71CrossRef
2.
Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Richard Webb W (2005) High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 172:488–493CrossRef
3.
Rozanski C, Mura M (2014) Multi-dimensional indices to stage idiopathic pulmonary fibrosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 31:8–18PubMed
4.
Serajeddini H, Rogliani P, Mura M (2018) Multi-dimensional assessment of idiopathic pulmonary fibrosis across a wide range of disease severity. Lung 196:707–713CrossRef
5.
Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167:962–969CrossRef
6.
Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176–183CrossRef
7.
Hosein K, Le J, Mura M (2017) Assessing the therapeutic response to pirfenidone in patients with idiopathic pulmonary fibrosis: can we do better than with forced vital capacity alone? Lung 195:101–105CrossRef
8.
Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Park SW, Jeong SH, Park YB, Lee HL, Shin JW, Lee EJ, Lee JH, Jegal Y, Lee HK, Kim YH, Song JW, Park MS (2018) Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 8:4784CrossRef
9.
Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R, Raghunath SM, Walsh SL, Wells AU, Hansell DM (2016) Automated quantitative computed tomography versus visual computer tomography scoring in idiopathic pulmonary fibrosis: validation against pulmonary function. J Thorac Imaging 31:304–311CrossRef
10.
11.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Mansour G, Nicholson AG, Popavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC (2018) Diagnosis of idiopathic pulmonary fibrosis. An officiant ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198:e44–e86CrossRef
12.
Flaherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ (2004) Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 170:904–910CrossRef
13.
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691CrossRef
14.
Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KR (2016) Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline. Chest 149:491–496CrossRef
15.
du Bois EM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Veleyre D, Weycker D, King TE Jr (2014) 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43:1421–1429CrossRef
Metadata
Title
The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version
Authors
Karishma S. Hosein
Gianluigi Sergiacomi
Maurizio Zompatori
Marco Mura
Publication date
01-02-2020
Publisher
Springer US
Published in
Lung / Issue 1/2020
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-019-00295-4

Other articles of this Issue 1/2020

Lung 1/2020 Go to the issue

COUGH

Abstracts from the Seventh American Cough Conference

PLEURAL DISEASE

Increased E/A Ratio is a Risk Factor for the Formation of Pleural Effusion in Heart Failure

SLEEP

Circulating P-Selectin Glycoprotein Ligand 1 and P-Selectin Levels in Obstructive Sleep Apnea Patients

CYSTIC FIBROSIS

Chloride Conductance, Nasal Potential Difference and Cystic Fibrosis Pathophysiology

ASTHMA

The Impact of Interleukin (IL)-33 Gene Polymorphisms and Environmental Factors on Risk of Asthma in the Iranian Population

PULMONARY REHABILITATION

Effects of Expiratory Muscle Training and Air Stacking on Peak Cough Flow in Individuals with Parkinson’s Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits